# Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults

> **NCT04894227** · PHASE4 · COMPLETED · sponsor: **Sinovac Research and Development Co., Ltd.** · enrollment: 1080 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Inactivated SARS-CoV-2 Vaccine (Vero cell）

## Key facts

- **NCT ID:** NCT04894227
- **Lead sponsor:** Sinovac Research and Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-11
- **Primary completion:** 2021-05-11
- **Final completion:** 2021-11-30
- **Target enrollment:** 1080 (ACTUAL)
- **Last updated:** 2022-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04894227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04894227, "Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04894227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*